From Journal of the American Herbalist Guild
A group of Indian and German scientists conducted an open, non-randomized pilot study to test the hypothesis that Boswellia might be beneficial for the treatment of ulcerative colitis. For the study, 34 patients (18 with
grade 11 and 16 with grade 3 colitis) were given 350 mg of Boswellia resin three times a day, and 8 patients (5 with grade 11 and 3 with grade 3 colitis) were given the drug sulfasalazine, 1 g three times a day. The authors commented that the cost of the drug was responsible for the small control group. Symptoms such as abdominal palms, loose stools, mucus, and blood Improved in both groups, with results for the control sulfasalazine group slightly better than the Boswellia group. |
Sigmoidoscopic examination for the grading of the disease and rectal biopsies both showed substantial improvements in the two treatment groups, and there was no statistically
significant difference between the groups. About 80% of the patients receiving Boswellia went into remission. The authors concluded that although they could not statistically confirm the superiority of Boswellia over sulfasalazine, the data suggest that it is at least not inferior.
Twenty patients with chronic colitis received Boswellia gum resin (900 mg per day for 6 weeks) and another 10 patients were given sulfasalazine (3 g per day for 6 weeks) in an open-label trial. Out of 20 patients treated with Boswellia, 14 went into remission (70% compared to 40% for sulfasalazine).
Journal of the American Herbalist Guild Vol 6 issue 1
significant difference between the groups. About 80% of the patients receiving Boswellia went into remission. The authors concluded that although they could not statistically confirm the superiority of Boswellia over sulfasalazine, the data suggest that it is at least not inferior.
Twenty patients with chronic colitis received Boswellia gum resin (900 mg per day for 6 weeks) and another 10 patients were given sulfasalazine (3 g per day for 6 weeks) in an open-label trial. Out of 20 patients treated with Boswellia, 14 went into remission (70% compared to 40% for sulfasalazine).
Journal of the American Herbalist Guild Vol 6 issue 1